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Abstract
Background—Inflammatory markers may be associated with recurrent vascular events after
stroke. We aimed to: (1) determine the association between interleukin-6, C-reactive protein,
fibrinogen and white cell count and recurrent vascular events after stroke, and (2) compare the
association between circulating inflammatory markers and the risk of death from vascular versus
non-vascular causes.
Methods and Results—We prospectively recruited patients with acute stroke (n=817) and
followed them for up to 4 years for the occurrence of: fatal or non-fatal recurrent stroke,
myocardial infarction or fatal vascular events, and death from any cause (n=159). The delay to
assessment was a median of 10 days. The adjusted incidence of the outcome cluster ‘recurrent
stroke, myocardial infarction or vascular death’ after stroke was significantly higher with higher
levels of interleukin 6 (75th to 25th centile: hazard ratio [HR] 1.56, 95 % CI 1.37 to 1.77), C-
reactive protein (75th to 25th centile HR 1·08, 95% CI 1·04 to 1·11) and fibrinogen (75th to 25th
centile HR 1.45, 95% CI 1.24 to 1.72). The associations between inflammatory markers and death
were stronger than with recurrent vascular events. The associations of inflammatory markers with
vascular and non-vascular deaths were similar.
Conclusions—Though inflammatory markers were associated with an increased risk of
recurrent vascular events and vascular death after stroke, they were also associated with non-
vascular causes of death, suggesting that inflammatory markers do not play a causal role
specifically in the generation of recurrent vascular events after stroke. Future studies of the
prediction of recurrent vascular events after stroke should concentrate on clinical variables, or
different blood markers.
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INTRODUCTION
In prospective studies of patients with prior stroke or transient ischemic attack (TIA),
increased levels of markers of acute inflammation – C-reactive protein (CRP)1, interleukin-6
(IL-6)2, fibrinogen1, 3 and white cell count4 – were associated with increased incidence of
recurrent stroke and myocardial infarction (MI) and the risk of death or disability at 6
months after stroke5. If high levels of acute-phase markers in the early stages of stroke
contribute to recurrent vascular events, we hypothesised the association between
inflammatory markers with fatal recurrent vascular events would be stronger than with
other, non-vascular, deaths.
In a prospective cohort of patients with recent stroke we aimed to: (1) estimate the
association between levels of circulating inflammatory markers and the incidence of
‘recurrent vascular events’ (recurrent stroke, MI and vascular death), and, (2) compare the
strength of the association between inflammatory markers and the risk of death from
vascular and non-vascular causes.
METHODS
The Edinburgh Stroke Study was a prospective, hospital-based cohort study of stroke
patients followed up for recurrent stroke, MI and death. We have described the methods and
process of data collection elsewhere6. In brief, we recruited consenting patients with
ischemic stroke or intracerebral hemorrhage presenting to the Western General Hospital in
Edinburgh between April 2002 and May 2005. We assigned ischemic stroke subtypes (i)
according to the site and size of the causative infarct, modified if necessary by imaging
findings with the Oxford community stroke project (OCSP) classification and (2) with a
modified Trial of ORG10172 in Acute Stroke Treatment (TOAST) classification as
described previously.6 We made a clinical assessment at baseline and contemporaneously
drew blood for markers of inflammation (CRP, IL-6, fibrinogen and white cell count and
glucose). We obtained follow up data on patients with multiple overlapping methods. We
defined as ‘recurrent vascular events’ the outcome cluster ‘recurrent fatal or non-fatal stroke,
subsequent fatal or non-fatal MI or other vascular death’. We defined ‘other vascular death’
as deaths due to athero-thrombo-embolic vascular diseases other than stroke or MI. For this
study we classified deaths due to the qualifying – though not recurrent - stroke (which were
most often due to pneumonia) or gastrointestinal hemorrhage as non-vascular. We did not
routinely record the occurrence of infections or other complications between stroke onset
and the measurement of vascular outcome or death. The Lothian Research Ethics Committee
approved the project.
Measurement of blood markers
A clinical laboratory measured total white cell count (Beckman Coulter LH750 analyser)
and blood glucose (Vitros Chemistry analyser). Blind to clinical details, we measured CRP
and fibrinogen in plasma by immunonephelometry (Prospec, Dade Behring Milton Keynes,
UK) using the manufacturer's reagents and standards. We assayed IL-6 by ELISA (R & D
Systems, Oxford, UK). Intra- and inter-assay coefficients of variation were 4.7 and 8.3%,
2.6 and 5.3%, and 7.5 and 8.9%, respectively.
Statistical analysis
We used Stata version 10 (Statacorp 2007) for analysis and prepared the paper with
reference to the STrengthening the Reporting of OBservational studies in Epidemiology.
(STROBE)7 guidelines. We measured survival to first recurrent vascular event, and
separately to each of recurrent stroke, MI and vascular death censoring patients at the end of
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follow up or non-vascular death. We compared the baseline characteristics of patients who
experienced a recurrent vascular event with those who did not with univariable Cox
regression analysis. We examined the relationships between inflammatory markers with
correlation coefficients, and used linear regression (after loge transformation of markers) to
examine the relationship of markers with delay to blood draw. We used Kaplan Meier
survival curves to compare event free survival between groups of patients defined by thirds
of inflammatory biomarkers and compared curves with log rank trend tests. We used Cox
regression analysis to calculate unadjusted hazard ratios (HR) and 95% confidence intervals
(CI) per unit increase in marker levels. We built a multivariate Cox regression model to
adjust for confounders, adding variables sequentially that were associated with recurrent
vascular events in univariable analysis and had data completeness of over 95%, keeping
those variables that significantly improved the fit of the model (likelihood ratio test P<0·05).
When the model was complete we tested the proportional hazards assumption and its
goodness of fit. We looked for first order interactions of inflammatory biomarker levels with
other variables in the final model by adding multiplicative terms.
We made further assessment of the marker most strongly associated with recurrent vascular
events (IL-6). We assessed the change in discrimination after the addition of IL-6 to a model
containing only clinical variables by calculating Harrell's c-statistic for models with and
without biomarkers. The c-statistic is analogous to the area under a receiver operator curve
for Cox regression models; a value of 0.5 indicates no better discrimination than chance and
a value of 1 perfect discrimination.
We replicated the analysis measuring time to death only, censoring at the end of the study.
To adjust models examining the risk of death, we used previously validated covariates. 8 We
also plotted, by thirds of marker levels, the competing risks of vascular deaths, death due to
the initial stroke and death due to other causes using the ‘stcompet’ command, 9 which
calculates the cumulative incidence of each outcome.
RESULTS
Baseline characteristics
877 of 1408 patients in the Edinburgh Stroke Study (62%) gave consent and were available
for blood to be drawn for markers of inflammation. Of these, 817 (93%) had a definite
ischemic stroke, 17 (2%) a probable ischemic stroke and 43 (5%) a hemorrhagic stroke. Of
those patients who had blood drawn for blood markers, none was lost to follow up for the
outcomes of death, recurrent stroke or myocardial infarction. We first assessed patients
clinically at a median of 10 days (IQR 3 to 21 days) after stroke onset and drew blood at a
median of 0 days (IQR 0 to 3 days) after assessment. The delay to assessment was longer for
outpatients seen in a clinic (median 19 days) than in those admitted to the stroke unit
(median 2 days). Patients who did not have blood drawn were similar to those with blood
drawn for biomarker data in age, sex distribution and the proportions with hypertension,
peripheral or cardiac vascular disease, diabetes or atrial fibrillation. On average, compared
to those without blood sampling, patients with blood samples had milder strokes (proportion
TACS 6.8 % vs 14.7% p=0.001), as patients admitted to hospital and those with more severe
symptoms were less likely to be recruited because of practical barriers to obtaining and
processing research blood samples and obtaining informed consent or assent.
During the 1866 person years of follow up (mean 2.12 years), 106 patients had a first
recurrent stroke (92 ischemic, 5 hemorrhagic and 9 of uncertain type) and 34 had a
myocardial infarction. There were 184 deaths: 113 from vascular causes (63 strokes, 35
from cardiac causes, and death from bowel ischemia, vascular dementia and presumed
vascular renal failure) and 64 from other causes (33 cancers, 13 chest infections, 6 from
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COPD and the rest from pancreatitis, bowel perforation, hip fracture, and extra-pulmonary
sepsis).
At the time of the clinical assessment of the index stroke, the median IL-6 was 4·0
(interquartile range [IQR] 2.4 to 7.2) pg/l, median CRP 3.5 (IQR 1.4 to 9.7) mg/l, median
fibrinogen 4.5 (IQR 3.8 to 5.4) g/l, median white cell count 8 (IQR 6.6 to 9.7) ×109/l and
median glucose 5.6 (IQR 5 to 6.8) mmol/l. The correlation coefficients were, between IL-6
and other variables were: CRP 0.59, fibrinogen 0.48, glucose 0.06 and white cell count 0.25.
The correlation coefficients between loge marker levels and delay from symptom onset to
blood draw were, for IL-6 −0.18, CRP −0.12, fibrinogen −0.11, white cell count −0.13 and
glucose −0.06. The relationships of average marker levels with the delay from stroke to
blood draw were not statistically significant after adjusting for the level of baseline
neurological impairment and age.
Circulating inflammatory markers and recurrent stroke, MI and vascular death
There was a significant increase in recurrent vascular events for patients who: were older; or
had a history of AF, heart failure or previous peripheral vascular disease, coronary heart
disease or stroke (Table 1). The log hazard of stroke, MI or vascular death rose with each
third of IL-6 and CRP, though not by thirds of glucose, fibrinogen or white cell count.
In unadjusted Kaplan-Meier survival analyses, patients survived free of recurrent vascular
events for a shorter time in the highest third of IL-6 (log rank trend χ2=13.2, p=0.0003)
(figure 1) and CRP (log rank trend χ2=13.9, p=0.0002). This relationship did not reach
statistical significance for fibrinogen (log rank trend χ2=2.8, p=0.09), glucose (log rank
trend χ2=1.1, p=0.3) or white cell count (log rank trend χ2=3.1, p=0.08). However, a linear
model fitted the data well for each marker.
Table 2 shows the association between circulating inflammatory markers and recurrent
vascular events. In univariate analyses, all markers except glucose were significantly
associated with recurrent vascular events. The relative hazard for an increase of 1 pg/ml of
IL-6 was 1.07 (95% CI: 1.04 to 1.10) per pg/ml. The unadjusted associations between IL-6
and recurrent fatal or non-fatal stroke alone (HR 1.04 95% CI 1.00 to 1.08 per pg/ml) were
weaker while the HRs for a mg/l increase of CRP, a g/l increase of fibrinogen, a 1×109
increase in white cell count or a mmol/l increase of glucose were not significantly different
from 1. The unadjusted association between IL-6 and fatal or non-fatal MI alone (HR 1.09,
95% CI 1.03 to 1.15) was stronger than for recurrent stroke alone.
We adjusted for the following confounders in the final model: age, prior stroke or TIA or
ischemic heart disease, current or prior AF and cardiac failure. Adding markers of stroke
severity (i.e. ability to walk or lift arms off bed), blood pressure at assessment, stroke
pathological type, diabetes, carotid stenosis, delay to blood taking or smoking did not
significantly improve models containing a single inflammatory marker. After adjustment,
there was still a significant association between recurrent vascular events and increasing
levels of IL-6, CRP and fibrinogen (Table 2). In this cohort, those patients with highest
blood levels (75th centile) of interleukin 6 had a 1.33 fold increase in the incidence of
recurrent vascular events compared with those with the lowest levels (25th centile). A
similar relative increase in incidence was seen for fibrinogen (HR 1.20), and less for C-
reactive protein (HR 1.06).
We added markers sequentially as continuous variables, in order of the strength of their
association with recurrent vascular events, to a model containing only clinical variables
(age, prior stroke or TIA or heart disease, current or prior AF or cardiac failure). Addition of
IL-6 significantly improved the model (likelihood ratio (LR) test χ2=14.0, p<0.001), though
Whiteley et al. Page 4
Stroke. Author manuscript; available in PMC 2011 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
further addition of CRP (LR test χ2=0.3, p=0.56), fibrinogen (LR test χ2=0.2, p=0.68),
white cell count (LR test χ2=0.7, p=0.40), or glucose (LR test χ2=1.3, p=0.25) did not make
further improvement, probably as the markers were correlated. After adjustment for all
markers, only the association between IL-6 and recurrent vascular events remained
statistically significant. The final model including IL-6 fulfilled the proportional hazards
assumption and fitted the data well.
A model with only clinical variables (age, prior TIA, MI or stroke and AF) had a Harrell's c
statistic of 0.62; when we added interleukin-6 to this model, the Harrell's c statistic increased
by a small amount, to 0.64.
Modification of associations by baseline variables
Multiplicative interaction terms between delay to blood taking after stroke, large vessel
stroke versus all others (with a modified TOAST algorithm), age, ability to walk and level of
IL-6 did not make important changes to the association between IL-6 and recurrent vascular
events (and none significantly improved the fit of the final Cox proportional hazards model).
This means that, for example for the variable ‘delay to blood taking’, we were unable to
demonstrate a difference in the association between IL-6 and recurrent vascular events in
those where blood was taken early (<5 days) or later (>5 days) after stroke. There were no
significant two way interactions between other blood markers and IL-6.
Circulating inflammatory markers and death
All markers were significantly associated with an increased risk of death (Table 3). After
adjustment for factors which are known reliably to influence survival after the index stroke
(age, being able to walk or talk, independence of daily activities prior to stroke, being able to
lift arms from the bed), these associations remained statistically significant though
attenuated. IL-6, CRP, fibrinogen and glucose were more strongly associated with death
than with recurrent vascular events, though white cell count was less strongly associated.
After additional adjustment for all other markers, only the associations of IL-6 and
fibrinogen with death remained statistically significant. The association between higher
levels of IL-6, CRP and fibrinogen and an increased incidence of death was consistent for
each of the separate causes of death (vascular deaths, deaths due to the initial stroke and
deaths due to other causes) (figure 2, data for CRP and fibrinogen not shown). Where the
cause of death was the qualifying stroke, patients in the top third of the IL-6 distribution had
the shortest survival time.
DISCUSSION
In this cohort consisting of stroke patients on the stroke unit assessed soon after onset and of
outpatients with milder strokes seen after a short interval, higher levels of IL-6, CRP and
fibrinogen were associated with a higher incidence of recurrent stroke, MI or vascular death,
independent of atrial fibrillation, prior vascular events and age. In addition, higher levels of
each inflammatory marker were associated with a higher incidence of death from all causes,
an association that was stronger than for all vascular events. The association with recurrent
stroke alone was weak for IL6, and did not reach statistical significance in this cohort for the
other markers.
We found no consistent evidence of different strengths of association between higher levels
of IL-6 with large vessel type strokes versus other stroke subtypes, strokes of different
severity or different times from stroke onset to blood draw. Stroke patients had qualitatively
similar associations between IL-6, CRP and fibrinogen and deaths from vascular and from
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non vascular causes. However, there was a suggestion that early deaths from the index
stroke might be more strongly associated with higher levels of inflammation.
Strengths and limitations
This study had a number of methodological strengths: the cohort included both mild and
severe strokes; we used several overlapping methods to ensure we detected all recurrent
vascular events; we determined vital status at the end of the follow up period for all of the
cohort; data on all suspected outcome events were checked by the study clinicians, either
directly or by review of the medical and imaging records. The majority of patients with
recurrent strokes underwent repeat brain imaging (93%).
We were unable to draw blood for inflammatory markers from all patients. The most
common reasons for not drawing blood were: either the patient did not consent or the
practical constraints in inpatients (chiefly the working hours of research laboratories
handling the samples). Patients without blood samples tended to have more severe strokes
though were otherwise similar (there was no evidence of an interaction between stroke
severity and the association between inflammatory markers and either recurrent vascular
events or death). These selection biases may have influenced the results.
We drew blood as soon as possible after assessment (median 2 days among patient admitted
to hospital); hence levels of IL-6 and CRP were higher than in previous studies (delay to
blood draw in these studies was between 12 hours and 30 days), possibly due in some cases
to stroke complications such a pneumonia or deep vein thrombosis. As we were unable to
adjust for these in our analysis, the observed association may have been due to confounding
by these complications. However, in the 60% of patients seen as outpatients, who had milder
strokes, and probably fewer infections or other complications, the median time to blood
draw was 19 days. Despite this, we were unable to demonstrate effect modification by the
time to blood draw after stroke on the association between either IL-6 or CRP and recurrent
vascular events, though statistical tests for effect modification are of low power. It is also
possible that among patients in whom the initial assessment was delayed, we may have
overlooked some early recurrent strokes.
We did not find that large vessel stroke subtypes had a stronger association between marker
levels and recurrent events. However, a relatively large number of strokes were unclassified
by the TOAST classification, so we cannot exclude the possibility that an association exists.
We used a competing risks survival analysis to examine the association of IL-6, fibrinogen
and CRP with of the three main causes of death; vascular, non-vascular and deaths due to
the initial stroke. It is possible that there was some misclassification of the cause of death,
particularly for deaths occurring soon after stroke when accurate attribution of the cause of
death is difficult, even if autopsy is performed.
The epidemiological association between inflammatory markers and recurrent vascular
events appears consistent and strong, and similar for IL-6 and CRP, though a somewhat
weaker for fibrinogen. However, the degree of extra clinical utility obtained by adding an
inflammatory marker to a clinical predictive model is not merely determined by the fact that
it is a statistically independent predictor in multivariate models. The small increase in the c-
statistic achieved by adding IL-6 to a model based upon clinical variables makes it unlikely
that it will add clinically useful prediction to models based on variables that do not require
blood draw. We did not calculate a threshold of IL-6 that best predicted recurrent vascular
events, as such calculations usually lead to a biased assessment of the strength of predictive
ability of markers and are unlikely to be replicated in validation cohorts.10
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Interpretation
These data suggest that CRP or IL-6 may not have a major causal role in recurrent vascular
events after stroke. It is more likely that the observed association reflects an inflammatory
response either to atherosclerosis or to its risk factors, or to an as yet unidentified trigger. In
support of this, studies that have examined functional CRP and IL-6 polymorphisms (which
produce differences in baseline CRP or IL-6 levels) found different polymorphisms were not
associated with an increased risk of stroke11 or other occlusive vascular events12. However,
to determine reliably any causal relationship between the physiological inflammatory
response and recurrent vascular events in humans would require a randomised trial of an
agent which was an effective anti-inflammatory but had no direct effect on other vascular
risk factors such as cholesterol or blood pressure.
Generalisability
Our finding that IL-6 showed the strongest association with recurrent vascular events and
with death in this cohort of stroke patients, is consistent with recent reports from population-
based prospective studies. 13 14 Our estimates of the association between: (i) CRP, IL-6,
fibrinogen and recurrent stroke, 1, 15 16 and (ii) CRP, fibrinogen and death16, 17 are
consistent with previous studies (supplementary table 1).
Conclusions
We have demonstrated an association between higher levels of IL-6, CRP and fibrinogen
and an increased incidence of occlusive vascular events in patients after stroke. The
association between IL-6, CRP and fibrinogen and fatal vascular and non-vascular events
after stroke seems similar. Future studies of prediction of recurrent vascular events after
stroke might better study easily measured clinical variables, or examine the effect of
different blood markers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Unadjusted Kaplan Meier survival curve and life table, for survival free from recurrent
stroke, myocardial infarction or vascular death by third of interleukin 6.
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Figure 2.
Unadjusted cumulative incidence curves of (a) death from recurrent stroke, MI or other
vascular causes, (b) death from the initial stroke with no evidence of recurrent stroke or (c)
other non-vascular deaths, by thirds of interleukin 6, estimated from a competing risk
analysis.
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Table 1
Baseline characteristics of stroke patients.
Total Recurrent Stroke, MI
or vascular death
No vascular event Univariate HR
(95% CI)
Number 877 159 718
Demographic
Age, years (mean, SD) 71.4 (12.0) 73.6 (10.7) 70.9 (12.2) 1.02 (1.00 – 1.04)†
Male sex, N (%) 463 (52.8) 80 (50.3) 383 (53.3) 0.9 (0.6 to 1.2)
Laboratory results Median (IQR) Median (IQR) Median (IQR)
Interleukin-6 (pg/ml) 4.0 (2.4-7.2) 4.8 (2.8-9.1) 3.8 (2.3-6.6)
CRP (mg/L) 3.5 (1.4-9.7) 5.9 (1.9-15.5) 3.3 (1.2-8.8)
Fibrinogen (g/L) 4.5 (3.8-5.4) 5.7 (3.9-5.7) 4.4 (3.8-5.4)
White cell count (×109/l) 8 (6.6-9.7) 8.4 (6.7-9.7) 7.9 (6.6-9.7)
Glucose (mmol) 5.6 (5-6.8) 5.7 (4.9-7.2) 5.6 (5-6.7)
Cholesterol (mmol/l) 5.1 (4.4-6.0) 4.9 (4.3-5) 5.1 (4.4-6)
Pathological type, index stroke N (%) N (%) N (%)
Definite ischemic 817 (93.2) 149 (93.7) 668 (93.0) 1.1 (0.6 to 2.1)‡
Definite hemorrhagic 43 (4.9) 9 (5.7) 34 (4.7) 1.2 (0.6 to 2.4) ‡
Pathological type unknown 17 (1.9) 1 (0.6) 16 (2.2) 0.3 (0.1 to 1.9) ‡
Clinical stroke syndrome of index
stroke (OCSP*)
TACI 57 (6.8) 10 (6.3) 53 (7.4) 1.2 (0.6 to 2.2) §
PACI 376 (45.1) 81 (50.9) 308 (42.9) 1.1 (0.8 to 1.6) §
LACI 228 (27.3) 38 (23.9) 200 (27.9) 0.8 (0.5 to 1.1) §
POCI 131 (15.7) 22 (13.8) 121 (16.9) 0.8 (0.5 to 1.3) §
Uncertain subtype 42 (5.0) 8 (5.0) 36 (5.0) 0.9 (0.5 to 1.9) §
Severity of index stroke
Can't walk, can't lift both arms 91 (10.4) 12 (7.6) 79 (11.0) 0.9 (0.5 to 1.5)
Can't walk, can lift both arms 119 (13.6) 31 (19.5) 88 (12.3) 1.6 (1.1 to 2.4)
Can walk 664 (76.0) 115 (72.9) 549 (76.7) 0.7 (0.5 to 1.0)
Aetiological classification of index
stroke (TOAST)
Cardioembolic 117 (13.3) 28 (17.6) 89 (12.4) 1.2 (0.8 to 2.0) ∥
Large vessel disease 72 (8.2) 12 (7.6) 60 (8.4) 1.0 (0.7 to 1.6) ∥
Mixed aetiology 58 (6.6) 16 (7.6) 42 (5.9) 1.8 (1.2 to 2.7) ∥
Small vessel disease 178 (20.3) 24 (15.1) 154 (21.5) 0.8 (0.6 to 1.2) ∥
Unclassified after complete investigation 355 (40.5) 65 (40.9) 290 (40.4) 0.9 (0.7 to 1.3) ∥
Unclassified after incomplete investigation 40 (15.8) 14 (8.8) 83 (11.6) 0.8 (0.5 to 1.5) ∥
Risk factors
History of TIA 143 (16.3) 29 (18.2) 114 (15.9) 1.1 (0.8 to 1.7)
History of stroke 166 (18.9) 41 (25.8) 125 (17.4) 1.5 (1.1 to 2.2)
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Total Recurrent Stroke, MI
or vascular death
No vascular event Univariate HR
(95% CI)
History of ischemic heart disease 242 (27.6) 62 (39.0) 180 (25.1) 1.9 (1.4 to 2.6)
History of PVD 69 (7.9) 22 (13.9) 47 (6.6) 2.0 (1.3 to 3.2)
Ipsilat. carotid stenosis >70 97 (12.5) 21 (14.9) 76 (12.0) 1.2 (0.8 to 2.0)
Ever AF 168 (20.3) 42 (26.4) 126 (17.6) 1.7 (1.3 to 2.5)
Prior treated hypertension 467 (53.3) 96 (60.4) 371 (51.7) 1.4 (1.0 to 1.9)
Diabetes 110 (12.5) 26 (16.4) 84 (11.7) 1.4 (0.9 to 2.2)
Ever smoker 602 (69.8) 113 (71.1) 489 (69.5) 1.1 (0.8 to 1.5)
Heart failure 40 (4.58) 14 (8.7) 26 (3.6) 2.8 (1.6 to 4.8)
Any antiplatelet at baseline 369 (46.1) 11 (6.9) 33 (4.6) 1.7 (0.9 to 3.1)
Warfarin at baseline 43 (4.9) 32 (4.5) 11 (6.9) 1.5 (0.8 to 2.7)
Systolic BP (Mean, No.observations) 147.2 (874) 147.3 (159) 147.2 (715) 1.00 (0.99 to 1.01) †
Diastolic BP (Mean, No. observations) 80.0 (874) 80.1 (159) 80.0 (715) 1.00 (0.99 to 1.01) †
*OCSP=Oxfordshire Community Stroke Project Classification (ischemic and probable), TACS=total anterior circulation stroke, PACS=partial
anterior circulation stroke, LACS=lacunar stroke, POCS=posterior circulation stroke.
†per unit increase
‡
vs other pathological types
§
vs all others in OCSP classification
∥
vs all others in TOAST classification.
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Table 2
The association between marker level and recurrent stroke, MI or vascular death, assuming a linear association
between marker level and log hazards
Hazard ratio per unit increase* in marker (95% CI) Hazard ratio comparing 75th to 25st centile†
Unadjusted Adjusted‡ Adjusted for all
markers§
Adjusted‡
Interleukin-6 (pg/ml) 1.07 (1.04 to 1.10) 1.06 (1.03 to 1.09) 1.05 (1.01 to 1.09) 1.33 (1.15 to 1.53)
C-reactive protein (mg/l) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01) 1.00 (1.00 to 1.03) 1.06 (1.02 to 1.09)
Fibrinogen (g/l) 1.16 (1.05 to 1.28) 1.12 (1.01 to 1.25) 1.02 (0.97 to 1.17) 1.20 (1.01 to 1.43)
White cell count (×109/l) 1.06 (1.02 to 1.10) 1.05 (1.00 to 1.11) 1.03 (0.97 to 1.09) 1.17 (0.98 to 1.38)
Glucose (mmol/l) 1.04 (0.99 to 1.09) 1.03 (0.98 to 1.08) 1.02 (0.97 to 1.08) 1.06 (0.97 to 1.15)
*for IL-6 pg/ml; CRP mg/l; fibrinogen g/l; white cell count ×109/l; glucose mmol/l
†25th and 75th percentile respectively for: IL6 2.39 and 7.22 pg/ml; CRP 1.39 and 9.65 mg/l; fibrinogen 3.81 and 5.41 g/l; white cell count 6.6 and
9.7 ×109/l; glucose 5.0 and 6.8 mmol/l
‡Adjusted for confounders: age, cardiac failure, atrial fibrillation (current or past), or prior stroke, TIA, peripheral vascular disease or MI.
§
adjusted for all confounder in previous column, and other markers.
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Table 3
The association between marker level and death from any cause, assuming a linear association between
marker level and log hazards
Hazard ratio per unit increase* in marker (95% CI) Hazard ratio comparing 75th to 25th centile†
Unadjusted Adjusted‡ Adjusted for all
markers§
Adjusted‡
Interleukin-6 (pg/ml) 1.13 (1.10 to 1.15) 1.10 (1.07 to 1.12) 1.07 (1.04 to 1.12) 1.56 (1.37 to 1.77)
C-reactive protein (mg/l) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01) 1.00 (1.00 to 1.81) 1.08 (1.04 to 1.11)
Fibrinogen (g/l) 1.37 (1.26 to 1.49) 1.26 (1.14 to 1.40) 1.14 (1.01 to 1.28) 1.45 (1.24 to 1.72)
White cell count (×109/l) 1.07 (1.02 to 1.12) 1.05 (1.00 to 1.11) 1.03 (0.97 to 1.09) 1.17 (1.00 to 1.37)
Glucose (mmol/l) 1.95 (1.02 to 1.10) 1.06 (1.02 to 1.11) 1.04 (0.99 to 1.09) 1.12 (1.03 to 1.21)
*for IL-6 pg/ml; CRP mg/l; fibrinogen g/l; white cell count ×109/l; glucose mmol/l
†25th and 75th percentile respectively for: IL6 2.39 and 7.22 pg/ml; CRP 1.39 and 9.65 mg/l; fibrinogen 3.81 and 5.41 g/l; white cell count 6.6 and
9.7 ×109/l; glucose 5.0 and 6.8 mmol/l.
‡Adjusted for confounders: age, ability to walk, living alone, independent prior to stroke, orientated to place time and person, able to lift arms from
bed.
§
adjusted for all confounder in previous column, and other markers
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